Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer.


Journal

Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955

Informations de publication

Date de publication:
08 2019
Historique:
received: 27 02 2019
revised: 08 04 2019
accepted: 11 04 2019
pubmed: 18 5 2019
medline: 17 4 2020
entrez: 18 5 2019
Statut: ppublish

Résumé

Complete transurethral resection of bladder tumor (TURBT) is the initial procedure of choice for non-muscle-invasive bladder cancer, but its quality is far from optimal in clinical practice. We evaluated the existing body of evidence substantiating current quality control indicators (QCIs) for TURBT. A literature search was performed using PubMed and Embase, and selected articles were reviewed according to their level of evidence. Disease recurrence and progression were used as the primary end points. No hard evidence supports complete resection as a QCI, but rationally, it is the most important indicator for TURBT. A repeat resection is an important QCI in high-risk disease patients, but evidence suggests that it may not be necessary when detrusor muscle is present in the initial resection specimen. The presence of detrusor muscle in the resection specimen is a validated QCI for TURBT. Adjuvant intravesical instillation is a scientifically proven QCI. Bladder perforation is a controversial QCI in the existing literature. No evidence indicates the ideal time frame for the initial TURBT; thus, initial therapy in the first 6 weeks after diagnosis is not a good QCI. Three of the 6 proposed QCIs for TURBT are supported by evidence. Our literature analysis indicated the use of complete resection, repeat resection, the presence of detrusor muscle, and intravesical instillation are QCIs to minimize recurrence and progression, and increase beneficial outcomes.

Identifiants

pubmed: 31097388
pii: S1558-7673(19)30140-5
doi: 10.1016/j.clgc.2019.04.014
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e784-e792

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Murat Akand (M)

Department or Urology, University Hospitals Leuven, Leuven, Belgium; Department or Urology, Selçuk University, School of Medicine, Konya, Turkey. Electronic address: drmuratakand@yahoo.com.

Tim Muilwijk (T)

Department or Urology, University Hospitals Leuven, Leuven, Belgium.

Yannic Raskin (Y)

Department or Urology, University Hospitals Leuven, Leuven, Belgium.

Maxime De Vrieze (M)

Department or Urology, University Hospitals Leuven, Leuven, Belgium.

Steven Joniau (S)

Department or Urology, University Hospitals Leuven, Leuven, Belgium.

Frank Van Der Aa (F)

Department or Urology, University Hospitals Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH